...
首页> 外文期刊>Advances in Interventional Cardiology: Postepy w Kardiologii Interwencyjnej >The Zabrze’18 protocol is a feasible option to reduce the number of endomyocardial biopsies after heart transplantation
【24h】

The Zabrze’18 protocol is a feasible option to reduce the number of endomyocardial biopsies after heart transplantation

机译:Zabrze’18协议是减少心脏移植后心内膜活检数量的可行选择

获取原文

摘要

Limited diagnostic yield of endomyocardial biopsy after heart transplantation Endomyocardial biopsy (EMB) is the method of choice to assess the potential rejection episodes in post-transplant heart recipients [1]. Since it is an invasive procedure, it is associated with the risk of complications. Therefore, many attempts have been made to monitor the risk of potential rejection in a non-invasive manner. Among them, IMAGE and the CARGO gene-expression profiling protocols ultimately proved to be promising. Nevertheless, in most of the heart transplant centers across the world, EMB remained the gold standard to monitor rejection episodes. Moreover, the majority of the institutions developed local regimens of patient surveillance after heart transplantation (HTx). They can be divided into two main groups, depending on the general assumptions. The first is focused on the high number of EMBs performed according to a routine schedule (routine surveillance EMB – rsEMB), which in theory enables the diagnosis and treatment of acute cellular rejection (ACR) episodes before the development of clinical signs of rejection. The second concept focuses on clinical symptoms that are believed to trigger EMB, which is performed in case of ACR suspicion – clinically driven EMB (cdEMB). Since the diagnostic yield of rsEMB is limited, which means that the majority of the results are unable to prove rejection, it has been postulated to decrease the number of routinely performed EMBs [2]. Possible short- and long-term complications of EMB – from experimental to routine practice EMBs – were first performed by the Japanese cardiac surgeons Sakakibara and Konno in 1962, with the latter being considered the inventor of the method [3]. Likewise, EMB was introduced to clinical practice by Caves and colleagues in 1974 [4]. Interestingly, Japanese scientists made a significant contribution to the development and improvement of this technique. Nevertheless, due to medical–legislative reasons the national transplantation program in Japan for many years stayed below the national demands and possibilities. It should be emphasized that EMB, although widely characterized in the literature as a relatively safe technique with only a few unfavorable outcomes, may be associated with either acute or delayed complications – its frequency varies between 3% and 6% [5, 6]. Right ventricle perforation with the subsequent pericardial tamponade (0.5–2.6%) pneumothorax...
机译:心脏移植后心内膜活检的诊断率有限心肌内膜活检(EMB)是评估移植后心脏受体潜在排斥反应的一种选择方法[1]。由于这是一种侵入性手术,因此与并发症风险相关。因此,已经进行了许多尝试以非侵入性方式监测潜在排斥的风险。其中,IMAGE和CARGO基因表达谱分析方案最终被证明是有前途的。尽管如此,在世界上大多数心脏移植中心,EMB仍然是监测排斥反应的金标准。此外,大多数机构在心脏移植(HTx)之后制定了局部患者监护方案。根据一般假设,它们可以分为两个主要组。第一个重点是按照常规时间表(常规监测EMB – rsEMB)执行大量EMB,从理论上讲,这可以在临床排斥反应出现之前诊断和治疗急性细胞排斥(ACR)发作。第二个概念集中在被认为会触发EMB的临床症状上,这是在怀疑ACR的情况下进行的-临床驱动的EMB(cdEMB)。由于rsEMB的诊断产量有限,这意味着大多数结果无法证明是拒绝的,因此推测它可以减少常规执行的EMB的数量[2]。 EMB的可能的短期和长期并发症-从实验到常规的EMB-最早是由日本心脏外科医师Sak​​akibara和Konno于1962年进行的,后者被认为是该方法的发明者[3]。同样,1974年,Caves及其同事将EMB引入临床实践[4]。有趣的是,日本科学家为这项技术的发展和改进做出了重大贡献。然而,由于医疗立法的原因,日本的国家移植计划多年来一直未达到国家要求和可能性。应该强调的是,尽管EMB在文献中被广泛地描述为一种相对安全的技术,仅有少数不良结果,但它可能与急性或延迟并发症有关–其发生频率在3%至6%之间[5,6]。右心室穿孔伴随后的心包填塞(0.5–2.6%)气胸...

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号